Drug Landscape ›
Bisacodyl 5 MG ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 14
Most-reported reactions
Diarrhoea — 2 reports (14.29%) Heart Rate Decreased — 2 reports (14.29%) Hyperhidrosis — 2 reports (14.29%) Vomiting — 2 reports (14.29%) Abasia — 1 report (7.14%) Abdominal Pain — 1 report (7.14%) Abdominal Pain Upper — 1 report (7.14%) Adverse Drug Reaction — 1 report (7.14%) Asthenia — 1 report (7.14%) Body Temperature Abnormal — 1 report (7.14%)
Source database →
Bisacodyl 5 MG in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Bisacodyl 5 MG approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Bisacodyl 5 MG in United States?
Parc Taulí Hospital Universitari is the originator. The local marketing authorisation holder may differ — check the official source linked above.